Lange JM, Laviana AA, Penson DF, et al. - Given that an accepted means of managing low-risk prostate cancer is active surveillance (AS), researchers focused on the comparative advantages of different AS schedules in men who received a diagnosis of prostate cancer and had Gleason score (GS) ≤ 6 disease and risk profiles similar to those in North American AS cohorts. On the basis of AS data from the University of Toronto, Johns Hopkins University, the University of California at San Francisco, and the Canary Pass Active Surveillance Cohort, times of GS upgrading were simulated. According to the findings, an acceptable alternative to more frequent biopsies can be obtaining a biopsy every 3 or 4 years among men diagnosed with GS ≤ 6 prostate cancer. A decrease in the number of biopsies, while preserving the benefit of more frequent schedules, was afforded by reducing surveillance intensity for those with a low risk of progression.